Fox Chase Makes a Splash at the 2016 AACR Annual Meeting

• 

  Fox Chase Cancer Center President & CEO, Richard Fisher, MD, hosted a reception at the Annual Meeting of the AACR on Sunday, April 17, 2016 from 7-9pm at the New Orleans Downtown Marriott at the Convention Center. View the reception photos on our Flickr page.

  ---

  

  Highlighted Research:

  Researchers from Fox Chase Cancer Center presented the findings of a neighborhood-wide association study (NWAS), a new computational approach that scanned over 14,000 neighborhood variables from the U.S. Census for associations with prostate cancer aggressiveness, at the AACR Annual Meeting 2016. 

  The study identified 17 neighborhood variables that were most significantly associated with advanced prostate cancer in white men.   

  ---

  Below is a list of Fox Chase and Temple University faculty who presented during the Annual Meeting. We look forward to connecting next year in Washington, D.C.

  Presentation Title:	Fox Chase Cancer Center Author:	Presentation Time:
  Inflammation and cancer	Sergei I. Grivennikov	Saturday, Apr 16, 2016, 10:15 AM -12:15 PM
  PAK1 inhibitor FRAX1036 sensitizes ovarian cancer cells with amplified 11q13 to cytotoxic effect of rottlerin	Tatiana Prudnikova, Jonathan Chernoff	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  Functional role of Pak1/Erk signaling in Rac1-related diseases	Daniela Araiza-Olivera, Jonathan Chernoff	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  Plk2 loss occurs commonly in colorectal carcinomas but not in adenomas	Elizabeth M. Matthew, Suraj Peri, Namrata Vijayvergia, Amriti Lulla, Eric Ross, Wafik El-Deiry	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  26 Sensitive step in cholesterol biosynthesis reveals role for sterol metabolites in regulating growth of EGFR/KRAS-dependent tumors	Linara Gabitova, Diana Restifo, Elizabeth Handorf, Kathy Q. Cai, Igor A. Astsaturov	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  327 Anti-tumor effect and destabilization of R175H-mutant p53 by CB002, a p53-pathway restoring small molecule that stimulates autophagy	Liz J. Hernandez Borrero, Shengliang Zhang, David Dicker, Wafik El-Deiry	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  331 Beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG	Wen-Chi Chang, Margie Clapper	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  349 Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201	Jessica Wagner	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  746 Transcriptional reprogramming of pancreatic stroma enhances chemotherapy and halts tumor growth	Janusz Franco-Barraza, Edna Cukierman	Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM
  LB-072 Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017	Hossein Borghaei	Sunday, Apr 17, 2016, 5:20 PM - 5:35 PM
  1584 Musashi-2 (MSI2) drives TGFBR1/SMAD3 dependent partial EMT and supports VEGFR2 expression and metastasis of human and mouse NSCLC cells	Alexander Deneka, Anna Nikonova, Ilya Serebriiskii, Tim N. Beck, Qi Cai, Brian L. Egleston, Emmanuelle Nicolas, Hossein Borghaei	Monday, Apr 18, 2016, 8:00 AM -12:00 PM
  1242 Combination of p21-activated kinase 1 (PAK1) inhibitor FRAX1036 and Aurora-A inhibitor alisertib is effective in hormone receptor-positive breast cancer	Vladislav Korobeynikov, Anna Nikonova, Jonathan Chernoff, Erica Golemis	Monday, Apr 18, 2016, 8:00 AM -12:00 PM
  1825 ONC201 induces cell death in androgen receptor positive prostate cancer cells and shows synergistic effect with anti-prostate cancer drugs	Avital Lev, Amriti R. Lulla, David T. Dicker, Wafik S. El-Deiry	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  1876 Reduced Pak1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition	Tatiana Prudnikova, Neil Johnson, Jonathan Chernoff	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  3087 Combination of ONC201 and bevacizumab significantly impacts colorectal cancer growth and metastasis in vivo	Jessica Wagner, Wafik S. El-Deiry	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  2266 Molecular and genomic characterization of SCLC	Hossein Borghaei	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  LB-209 D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies	Wafik S. El-Deiry	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  CT057 A single-arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery	Lori J. Goldstein	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  2302 An 'off the shelf,' GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics	Kerry Campbell	Monday, Apr 18, 2016, 1:00 PM - 5:00 PM
  CT065 Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results	Efrat Dotan, Steven J. Cohen	Monday, Apr 18, 2016, 3:15 PM - 3:30 PM
  2678 Notch1 regulates epithelial-mesenchymal transition and tumor-initiating capability in esophageal squamous-cell carcinoma	Andres J. Klein-Szanto	Monday, Apr 18, 2016, 3:35 PM - 3:50 PM
  2657 Target specificity of epigenetic therapy in cancer	Takahiro Sato, Matteo Cesaroni, Shoghag Panjarian, Anthony Tran, Jozef Madzo, Yasuyuki Okamoto, Hanghang Zhang, Xiaowei Chen, Jaroslav Jelinek, Jean-Pierre J. Issa	Monday, Apr 18, 2016, 3:35 PM - 3:50 PM
  2751 Frequent BRCA2 somatic mutations in colorectal cancer patients with microsatellite instability (MSI)	Safoora Deihimi, Avital Lev, Michael Slifker, Qifang Xu, David T. Dicker, Eric A. Ross, Roland Dunbrack, Jr., Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM
  2864 Role of ribosomal protein, Rpl22 in regulation of acute lymphoblastic leukemia	Nehal R. Solanki-Patel, Noa Greenberg, Shu Rao, Suraj Peri, Michael Slifker, Charles Mullighan, David Wiest	Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM
  2833 Genetic and pharmacologic inhibition of mTOR delays mortality due to thymc lymphoma formation in mice and is associated with decreases in cell cycle proteins	Jinfei Xu, Joseph R. Testa	Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM
  2840 CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxia in vitro	Jun Zhang, Lanlan Zhou, Shuai Zhao, David Dicker, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM
  3000 Intra-tumoral accumulation of NK1.1/CD3+ cells and anti-metastasis effects of dose-intensified ONC201 in tumor-bearing mice	Jessica Wagner, Christina L.B. Kline, Marie Baumeister, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM
  3816 Reactive oxygen species and ERK2 phosphorylation are required for NSC59984 to induce mutant p53 protein degradation and restore p53 signaling	Shengliang Zhang, Lanlan Zhou, David Dicker, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
  3309 Novel small molecule ONC201 induces cell death and targets chemotherapy-resistant cancer stem-like cells in triple negative breast cancer	Marie D. Baumeister, Jessica Wagner, Christina LB Kline, David T. Dicker, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
  3830 Synthesis and anticancer activity of novel prodigiosin analogs	Xiaobing Tian, Shengliang Zhang, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
  3706 p53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression following thymidylate synthase (TS) inhibition	Prashanth Ravishankar Gokare, Niklas Finnberg, Wafik S. El-Deiry	Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
  3662 Analysis of the tumor suppressor function of B55alpha, the PP2A regulatory subunit encoded by PPP2R2A, in prostate cancer cells	Ziran Zhao, Alison Kurimchak, Mary Adeyemi, Patrick Woodruff, Vladimir Kolenko, Xavier Graña	Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
  CT137 First-in-human study of AMG 820, a monoclonal anti-CSF-1R (c-fms) antibody, in patients (pts) with advanced solid tumors	Lainie P. Martin, Anthony J. Olszanski	Tuesday, Apr 19, 2016, 4:30 PM - 5:00 PM
  4351 A neighborhood-wide association study (NWAS) in prostate cancer: A new methodologic approach	Shannon Lynch	Tuesday, Apr 19, 2016, 4:35 PM - 4:50 PM
  5286 A pipeline for developing a novel, predictive tool to classify variants of uncertain significance (VUS) in Lynch Syndrome	Sanjeevani Arora, Peter J. Huwe, Rahmat Sikder, Manali Shah, Sanat Deshpande, Michael J. Hall, Roland L. Dunbrack, Jr., Erica A. Golemis	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  5248 ED-71, an analogue of Vitamin D3, blocks the promotion but not the initiation of colorectal tumors in the Apc+/Min-FCCC mouse model	Wen-Chi L. Chang, Harry S. Cooper, Esther Kaunga, Lisa Vanderveer, Jing Peng, Margie L. Clapper	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  4825 A rationale for treatment of colorectal cancer with mitomycin C and crizotinib	Avital Lev, Safoora Deihimi, David T. Dicker, Wafik S. El-Deiry	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  4826 ONC212 exhibits increased cytotoxicity relative to ONC201 in a subset of human pancreatic cancer cell lines	Avital Lev, Jessica Wagner, David T. Dicker, Wafik S. El-Deiry	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  5064 CORO1B amplification and expression status identifies an aggressive subset of chromosome 11q13 amplified HNSCC	Hong Wu	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  4923 Expression of class III beta-tubulin (TUBB3) in 3580 colorectal cancers (CRCs) and correlation with clinico-pathological and molecular features	Wafik S. El-Deiry	Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM
  Inflammatory microenvironment regulates colorectal cancer progression	Sergei I. Grivennikov	Wednesday, Apr 20, 2016, 10:45 AM -11:10 AM